Thymic carcinoma other diagnostic studies: Difference between revisions
No edit summary |
|||
| Line 8: | Line 8: | ||
===Immunohistochemistry=== | ===Immunohistochemistry=== | ||
For | For squamous cell carcinoma subtype, the epithelial cells are immunoreactive to CD5, CD70 and CD117. In contrast with thymomas that are negative to CD5. However, for squamous cell carcinomas of other locations, the CD5 and CD70 are negative, meaning that this is useful to confirm the thymic origin of the tumor. <ref>{{Cite web | last = | first = | title =http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/BB10.pdf | url = http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/BB10.pdf | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 18:20, 8 January 2016
|
Thymic Carcinoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Thymic carcinoma other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Thymic carcinoma other diagnostic studies |
|
Risk calculators and risk factors for Thymic carcinoma other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]Parminder Dhingra, M.D. [3]
Overview
Other diagnostic studies for thymic carcinoma include immunohistochemistry.
Other Diagnostic Studies
Immunohistochemistry
For squamous cell carcinoma subtype, the epithelial cells are immunoreactive to CD5, CD70 and CD117. In contrast with thymomas that are negative to CD5. However, for squamous cell carcinomas of other locations, the CD5 and CD70 are negative, meaning that this is useful to confirm the thymic origin of the tumor. [1]
References
- ↑ "http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/BB10.pdf" (PDF). External link in
|title=(help)